Sandesh Mahatme has replaced Tony Martignetti as Sarepta Therapeutics' (NASDAQ: SRPT ) chief accounting officer, the biotech said in a late Friday 8-K filing with the SEC. He will also remain as Serapta's chief financial officer.
Mahate joined Sarepta, a biotech specializing in therapies for genetic disorders such as Duchenne muscular dystrophy, last November from Celgene.
Martignetti's LinkedIn profile shows he'd been at Sarepta since September 2012. He joined the company after three years as managing partner at a real estate company and, before that, 1.5 years in commercial finance at Vertex Pharmaceuticals.
More than 37% of Sarepta's shares were sold short as of Oct. 1, making it one of the Nasdaq's five-most shorted stocks.